

MAXIM.073DV1C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : K. Gehlsen) Group Art Unit: Unknown
App. No. : Unknown)
Filed : Herewith)
For : METHODS AND)
COMPOSITIONS FOR TOPICAL)
TREATMENT OF DAMAGED)
TISSUE USING REACTIVE)
OXYGEN METABOLITE)
PRODUCTION OR RELEASE)
INHIBITORS)
Examiner : Unknown)

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
PO Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing references that were previously disclosed and/or cited by the Applicant in the prosecution in related applications hereto, U.S. Application No. 09/765,929, filed on January 19, 2001, which is a divisional of U.S. Application No. 09/227,801, filed on January 8, 1999, now U.S. Patent No. 6,270,781. The present application claims the priority date of the parent of this continuation application under 35 U.S.C. § 120. Copies of the references are not submitted pursuant to 37 C.F.R. § 1.98(d).

112
PATENT
5/3/02
1c971 U.S. PTO
10/068447
02/06/02

Appl. No. : Unknown
Filed : Herewith

This Information Disclosure Statement is being filed within three months of the filing date of this application, and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 6 P5B9002

By: 

James J. Mullen III, Ph.D.

Registration No. 44,957

Attorney of Record

620 Newport Center Drive

Sixteenth Floor

Newport Beach, CA 92660

(619) 235-8550

S:\DOCS\MKD\MKD-2481.DOC\020602

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. MAXIM.073DV1C1	APPLICATION NO. Unknown
	APPLICANT Gehlsen, K.R.	
	FILING DATE Herewith	GROUP Unknown

 1c971 U.S. PTO
 10/068447


U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
		4,307,076	12/22/81	Harvey et al.			
		4,573,996	03/04/86	Kwiatek et al.			
		4,597,961	07/01/86	Etscom			
		4,839,174	06/13/89	Baker et al.			
		4,857,328	08/15/89	Trenzeluk			
		4,908,213	03/13/90	Govil et al.			
		4,943,435	06/24/90	Baker et al.			
		5,166,620	05/26/92	Chvapil et al.			
		5,122,127	06/16/92	Stanley			
		5,160,731	11/03/92	Sabatelli et al.			
		5,288,497	02/22/94	Stanley et al.			
		5,294,440	03/15/94	Jack et al.			
		5,328,454	07/12/94	Sibalis			
		5,336,168	08/09/94	Sibalis			
		5,474,527	12/12/95	Bettinger			
		5,558,914	12/24/96	Cohen et al.			
		5,676,969	10/14/97	Wick et al.			
		5,679,337	10/21/97	Jack et al.			
		5,716,610	02/10/98	Jack et al.			
		5,804,203	09/08/98	Hahn et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		93/21904	11/11/93	WO				
		✓ 95/23601	09/08/95	WO				
		✓ 97/42968	11/20/97	WO				
		97/42968	11/20/97	WO				

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.073DV1	APPLICATION NO. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Gehlsen, K.R.	
		FILING DATE Herewith	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	A	Babior, et al., THE JOURNAL OF CLINICAL INVESTIGATION, 52(3): 714-744 (1973) "Biological Defense Mechanisms: The production by leukocytes of superoxide, a potential bacterial agent".
	B	Imamura, et al., PATHOLOGY INTERNATIONAL, 47(1): 16-24 (1997), "Involvement of tumor necrosis factor- γ , interleukin-1 β , interleukin-8, and interleukin-1 receptor antagonist in acute lung injury caused by local Schwartzman reaction".
C		Paul and Sbarra, BIOCHIMA ET BIOPHYSICA ACTA, 156: 168-178 (1968) "The Role of the Phagocyte in Host-Parasite Interactions".
	D	Martindale - The Extra Pharmacopoeia (Pharmaceutical Press, London 1993) and Martin (ed.), Remington's Pharmaceutical Sciences.
E		CFTA Cosmetic Ingredient Handbook, 2 nd Edition, eds. John A. Wenninger and G.N. McEwen, Jr. (CTFA, 1992).
	F	Anthony, L.L. (ed.), "A Formulary of Cosmetic Preparations (Vol. Two) - Creams, Lotions and Milks," Micelle Press (England, N.J., 1993).
G		http://www.shaperite.com/prod/pc24.html , "Smooth-Rite Pain Cream" (10/16/98)
	H	http://www.cyberspike.com/chiro/remedies/hist15.html , "Histamine", BioPharma - All Natural Homeopathic Remedies (12/21/98)
I		21 CFR Ch. 1 §310.545 (4-1-98 Edition)
	J	Brune, M. et al. (1996) NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. Eur.J.Haematol. 57:312-319.

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

S:\DOCS\MKD\MKD-2482.DOC
020602